Updated guidelines from the National Comprehensive Cancer Network list HER2 mutations as an emerging biomarker for targeted therapy with antibody drug conjugates (specifically, ado-trastuzumab emtansine and fam-trastuzumab deruxtecan-nxki). Access the full guidelines here.
Learn more about NSCLC treatment.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Maurie Markman. Fast Five Quiz: ERBB2 (HER2) Mutation in Non-Small Cell Lung Cancer - Medscape - Nov 23, 2021.